The global Digital Biomarkers Market is projected to grow from USD 6.30 billion in 2025 to USD 15.60 billion by 2030, registering a robust compound annual growth rate (CAGR) of 19.9% during the forecast period, according to a new research report titled “Digital Biomarkers Market by Product, Type, Disease Indication, End User – Global Forecast to 2030.”
The market’s rapid expansion reflects the accelerating adoption of wearable devices, remote monitoring technologies, mobile health applications, and AI-driven analytics, which are redefining how physiological and behavioral data are captured, analyzed, and translated into actionable clinical insights.
The report provides in-depth analysis across product types, disease indications, end users, and regions, supported by 408 market data tables, 56 figures, and 568 pages of detailed insights.
As healthcare systems increasingly prioritize continuous monitoring, decentralized clinical trials, and real-world evidence generation, digital biomarkers are emerging as a foundational component of next-generation healthcare delivery.
Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=7725399
Cardiovascular Disorders Lead by Disease Indication
By disease indication, cardiovascular disorders accounted for the largest share of the digital biomarkers market in 2024.
The dominance of this segment is driven by early clinical validation and widespread adoption of mobile- and wearable-based cardiac monitoring technologies. Digital biomarkers derived from ECG signals, heart rate variability, and rhythm analytics are now central to detecting and managing conditions such as atrial fibrillation, arrhythmias, and other cardiac abnormalities.
Strong clinical acceptance, regulatory clearances for software-based cardiac biomarkers, and integration into remote patient monitoring and telecardiology workflows have reinforced cardiovascular applications as the leading indication across hospital, outpatient, and home-care settings.
Mobile-Based Applications Register the Fastest Growth
By product, mobile-based applications are projected to register the fastest growth in the digital biomarkers market.
These applications leverage smartphones to enable continuous, real-world data collection at scale, supporting both passive and active capture of physiological, behavioral, and cognitive metrics. Their ability to support longitudinal monitoring, early disease detection, and treatment-response assessment—without requiring dedicated hardware—has significantly accelerated adoption. Mobile-driven digital biomarkers are gaining traction across cardiology, neurology, and mental health, reinforcing their importance in scalable, patient-centric healthcare models.
North America Maintains Market Leadership
The market for digital biomarkers is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America holds the largest share of the digital biomarkers market, reflecting its strong base of academic medical centers, integrated health systems, and digital health innovators that have rapidly adopted mobile-, wearable-, and software-based biomarker technologies. The region benefits from favorable reimbursement frameworks for remote patient monitoring, early regulatory acceptance of software-as-a-medical-device (SaMD), and major government and payer initiatives supporting digital health adoption.
Request For Sample Pages:- https://www.marketsandmarkets.com/requestsampleNew.asp?id=7725399
Competitive Landscape
The digital biomarkers market is characterized by innovation-driven competition and strategic collaborations between digital health companies and life sciences organizations. Key players include: Ametris (US), AliveCor (US), BioSensics (US), Mindstrong Health (US), iCOMETRIX (Belgium), BACtrack (US), AccuLabs (US), and AtCor Medical (Australia).
Strategic Outlook
With healthcare shifting toward preventive, personalized, and data-driven models, digital biomarkers are becoming integral to clinical trials, remote care delivery, and chronic disease management. Organizations investing in AI-enabled analytics, scalable software platforms, and regulatory-ready digital health solutions are expected to capture significant long-term value.
Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/digital-biomarker-market-7725399.html